Ionis Pharma: Clinical Study of Vupanorsen Meets Primary Endpoint
November 24 2021 - 7:29AM
Dow Jones News
By Robb M. Stewart
Ionis Pharmaceuticals Inc. said a clinical study of vupanorsen,
an investigational antisense therapy being developed for
indications in cardiovascular risk reduction and severe
hypertriglyceridemia that it licensed from Pfizer Inc., met its
main targets.
Pfizer reported topline results from a Phase 2b study which
found vupanorsen met its primary endpoint, achieving statistically
significant reduction in non-high density lipoprotein cholesterol
compared with a placebo at all doses tested, Ionis said
Wednesday.
The study's key secondary endpoints were met, including
statistically significant reductions in triglycerides and
angiopoietin-like-3 at all doses tested, Ionis said.
The company said Pfizer is continuing to review the findings to
determine the next steps for future development.
Vupanorsen was discovered by Ionis and is being developed by
Pfizer, which licensed it from Ionis in November 2019 in a
worldwide exclusive agreement.
In premarket trading, Ionis's shares were 1.2% higher after
ending the previous session at $30.33, down 46% since the end of
last year.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
November 24, 2021 07:14 ET (12:14 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Sep 2023 to Sep 2024